🧬Tidera Health
⚕️

Educational tool only. Does not confirm eligibility or provide medical advice. Always consult your physician before pursuing any trial.

OncologyICD-10: C61

Find Recruiting Clinical Trials for Prostate Cancer

Search mCRPC, hormone-sensitive, localized, and BRCA-positive prostate cancer trials matched to your PSA, stage, and prior treatment.

🔍 Search Prostate Cancer Trials →

About Prostate Cancer

Prostate cancer is the second most common cancer in men worldwide and the second leading cause of cancer death in American men. Most cases are detected through PSA (prostate-specific antigen) screening and digital rectal exam, and the majority of localized cases are curable with surgery or radiation. However, advanced prostate cancer that has spread beyond the prostate (metastatic) or progressed despite hormone therapy (castration-resistant) remains a major cause of mortality. Disease staging spans localized, locally advanced, metastatic hormone-sensitive (mHSPC), non-metastatic castration-resistant (nmCRPC), and metastatic castration-resistant (mCRPC) — each with distinct treatment options and trial landscapes. The androgen receptor (AR) pathway is central to prostate cancer biology; treatments include androgen deprivation therapy (ADT/LHRH agonists), AR pathway inhibitors (enzalutamide, abiraterone, darolutamide, apalutamide), PARP inhibitors (olaparib, rucaparib for BRCA/HRD), PSMA-targeted radioligand therapy (lutetium-177 PSMA-617), docetaxel, and cabazitaxel.

What Types of Prostate Cancer Clinical Trials Exist?

Prostate cancer trial eligibility is primarily determined by disease stage and prior treatment history. Localized disease trials test active surveillance protocols, radiation dose/fractionation, and surgical techniques. mHSPC trials test intensification of ADT with novel AR pathway inhibitors or chemotherapy doublets and triplets. nmCRPC trials test agents delaying metastasis onset (PSA doubling time is a key criterion). mCRPC trials — the most numerous — test novel AR antagonists, PARP inhibitors (BRCA1/2 or HRD mutation required for many), PSMA-targeted therapies (PSMA-PET positivity often required), immune checkpoint inhibitors, and combination strategies. Germline and somatic BRCA1/2, CDK12, and ATM mutation testing is increasingly essential. PSA level, PSMA-PET scan results, prior lines of therapy, and metastatic burden determine eligibility for advanced disease trials.

Find Recruiting Prostate Cancer Trials Near You

Enter your profile and we'll search ClinicalTrials.gov in real time — matching trials to your age, location, and treatment history. Free, no account required.

Search Prostate Cancer Trials →

Data from ClinicalTrials.gov · Updated in real time · Educational use only

Frequently Asked Questions

What clinical trials are available for prostate cancer?▾
Prostate cancer has one of the most active clinical trial pipelines in oncology. By disease stage: Localized prostate cancer trials test active surveillance optimization, focal therapy (HIFU, cryotherapy), radiation combinations, and post-treatment PSA monitoring strategies. Hormone-sensitive metastatic (mHSPC) trials test doublet and triplet intensification — combining ADT with novel AR pathway inhibitors (enzalutamide, abiraterone, darolutamide) and/or docetaxel, as well as next-generation combinations. Non-metastatic castration-resistant (nmCRPC) trials test agents in men with rising PSA and no visible metastases on conventional imaging but possible PSMA-PET lesions. Metastatic castration-resistant (mCRPC) trials — the largest category — test PARP inhibitors (for BRCA/HRD), PSMA radioligand therapies, bispecific antibodies, CAR-T cells, novel AR pathway agents, and immunotherapy combinations. Genetic testing (BRCA1/2, HRR panel) is strongly recommended before trial searching in advanced prostate cancer.
Does BRCA mutation status affect prostate cancer trial eligibility?▾
Yes, significantly — BRCA status has become one of the most important determinants of trial eligibility in advanced prostate cancer. BRCA1 and BRCA2 mutations (germline or somatic) are found in approximately 10–15% of mCRPC patients and indicate a deficiency in homologous recombination DNA repair (HRD). This opens eligibility for PARP inhibitor trials and approvals (olaparib for BRCA1/2; rucaparib for BRCA2; niraparib and talazoparib in combinations). Broader HRD mutations beyond BRCA (ATM, CDK12, CHEK2, PALB2) may also open trial eligibility depending on the specific study. Germline testing should be performed at a certified genetic counselor or through a tumor genomic profiling panel. CDK12 mutation, while not HRD, is associated with higher tumor mutational burden and may predict immunotherapy benefit. All men with metastatic prostate cancer should discuss genetic testing with their oncologist before ruling out trial eligibility.
What is mCRPC and how does it affect prostate cancer trial options?▾
mCRPC stands for metastatic castration-resistant prostate cancer — the stage where cancer has spread to other organs (typically bones and lymph nodes) AND continues to grow despite castrate levels of testosterone (achieved through ADT/LHRH agonists or bilateral orchiectomy). It is defined by PSA progression, radiographic progression, or symptomatic progression despite ongoing ADT, with confirmed castrate testosterone levels (<50 ng/dL). mCRPC represents the most advanced and treatment-resistant form of the disease and has the most active trial landscape. Patients with mCRPC may have already received one or two novel hormonal agents (enzalutamide, abiraterone) — prior treatment history determines eligibility for subsequent trials. Lines of therapy matter: many trials specify first-line mCRPC (no prior novel AR agent), second-line (one prior), or later-line populations. PSMA-PET scans are increasingly required to confirm PSMA expression for radioligand therapy trials.
Can I join a prostate cancer trial while on hormone therapy (ADT)?▾
Yes, in most cases — ADT (androgen deprivation therapy) is typically continued throughout prostate cancer trials, not stopped. For mHSPC and nmCRPC trials, ongoing ADT is almost always required as the treatment backbone; the investigational agent is added to or replaces components of the hormonal regimen. For mCRPC trials, ongoing ADT (to maintain castrate testosterone) is a standard requirement, as the definition of CRPC requires castrate testosterone levels. Some localized prostate cancer trials may test ADT with or without radiation and do not require pre-existing ADT. Importantly, prior ADT duration and the most recent PSA doubling time are commonly used eligibility criteria — particularly for nmCRPC trials, which often require a PSA doubling time of ≤10 months. Always bring your most recent PSA results, testosterone level, and medication list to any trial screening appointment.

Related Conditions

Breast CancerOvarian CancerColorectal Cancer

Data source: All clinical trial information is sourced from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Tidera Health is an independent educational platform and is not affiliated with ClinicalTrials.gov or the National Library of Medicine. Always verify trial details directly with the research coordinator or your physician.